1. Charmandari E, Nicolaides NC, Chrousos GP. Adrenal insufficiency. Lancet. 2014;383(9935):2152-2167. doi:10.1016/S0140-6736(13)61684-0
2. Arlt W, Allolio B. Adrenal insufficiency. Lancet (London, England). 2003;361(9372):1881-1893. doi:10.1016/S0140-6736(03)13492-7
3. Husebye E, Løvås K. Pathogenesis of primary adrenal insufficiency. Best Pract Res Clin Endocrinol Metab. 2009;23(2):147-157. doi:10.1016/j.beem.2008.09.004
4. Petríková J, Pura M, Lazúrová I. Antibodies to Gonadal and Adrenal Tissue. Autoantibodies. January 2014:391-405. doi:10.1016/B978-0-444-56378-1.00047-2
5. Hahner S, Allolio B. Therapeutic management of adrenal insufficiency. Best Pract Res Clin Endocrinol Metab. 2009;23(2):167-179. doi:10.1016/J.BEEM.2008.09.009
6. Oksnes M, Ross R, Løvås K. Optimal glucocorticoid replacement in adrenal insufficiency. Best Pract Res Clin Endocrinol Metab. 2015;29(1):3-15. doi:10.1016/j.beem.2014.09.009
7. Curtis JR, Westfall AO, Allison J, et al. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Care Res. 2006;55(3):420-426. doi:10.1002/art.21984
8. Nicolaides NC, Chrousos GP. Hypothalamic–Pituitary–Adrenal Suppression. Encycl Endocr Dis. January 2018:83-89. doi:10.1016/B978-0-12-801238-3.65817-8